Cryptophthalmos

Cryptophthalmos is a rare congenital anomaly where the eyelids are absent or fused, resulting in the eyes being covered by skin. Protheragen is at the forefront of developing innovative therapies for Cryptophthalmos. Our services span the entire therapeutic development pipeline, from initial drug discovery through to preclinical research.

Overview of Cryptophthalmos

Cryptophthalmos is a rare congenital anomaly characterized by the incomplete development or failure of separation of the eyelid folds during embryogenesis. This condition results in the eye being covered by epithelial tissue, leading to a range of secondary developmental eye anomalies such as corneal hypoplasia, microphthalmia, and disorganization of intraocular structures. The severity of cryptophthalmos varies along a phenotypic spectrum, from complete cryptophthalmos, where the eyelids are completely fused, to incomplete (partial) or abortive/congenital symblepharon forms.

Fig.1 Characterization of identified novel mutations in FREM2. (Yu Q., et al., 2018)

Genetic Basis of Cryptophthalmos

The genetic landscape of cryptophthalmos is diverse, with associations found with Fraser syndrome, amniotic band syndrome, FREM1-related disease, Goldenhar versus Schimmelpenning syndrome, MOTA syndrome, and CELSR2-related disease. Fraser syndrome, characterized by cryptophthalmos, syndactyly, and genitourinary malformations, is caused by biallelic pathogenic variants in FRAS1, FREM2, and GRIP1. The discovery of a possible association with biallelic CELSR2 variants marks a significant advancement, as CELSR2 is highly expressed in neural crest cells, eye, and brain, suggesting its critical role in ophthalmological disease.

Table 1. Analysis of genetic variation in cryptophthalmia. (Landau-Prat D., et al., 2023)

Diagnostics Development for Cryptophthalmos

The advancement in genetic diagnostics has significantly improved the identification of cryptophthalmos and its associated syndromes. Genetic testing can reveal the underlying mutations causing the condition, which is crucial for accurate diagnosis and prognosis. For instance, mutations in genes such as FREM2 have been linked to isolated cryptophthalmos, while Fraser syndrome, characterized by cryptophthalmos along with syndactyly and genitourinary malformations, is associated with mutations in FRAS1, FREM2, and GRIP1. These genetic insights enable targeted diagnostic approaches and pave the way for personalized therapeutics.

Our Services

Leveraging our expertise in genetic research and molecular biology, Protheragen is committed to providing a one-stop service for cryptophthalmos diagnostics and therapeutic development. Leveraging our extensive knowledge of the molecular pathways involved in cryptophthalmos, we are developing a pipeline of novel therapeutics. This includes small molecule drugs that target key proteins in eye development, as well as biologics that modulate immune responses and promote tissue regeneration.

Target Identification and Validation Services for Cryptophthalmos

Protheragen provides systematic target discovery and validation to identify druggable molecular drivers of cryptophthalmos. Using transcriptomic, proteomic, and epigenomic profiling of patient‑derived specimens and gene‑mutant cellular models, we prioritize genes and pathways regulating eyelid development, extracellular matrix integrity, cell adhesion, and tissue fusion. We perform in vitro functional validation via CRISPR‑Cas9 gene editing, RNA interference, and overexpression to confirm target roles in cryptophthalmos pathogenesis. Additional support includes pathway analysis, protein‑protein interaction mapping, and target druggability assessment to prioritize candidates for small‑molecule, biologic, or gene‑therapy intervention.

Cryptophthalmos Disease Model Development Services

We engineer physiologically relevant, human‑centric preclinical models to replicate key structural and molecular features of cryptophthalmos. Offerings include:

• Gene‑edited mammalian cell lines carrying FREM1, FREM2, FRAS1, or GRIP1 mutations for high‑throughput screening.
• 3D human eyelid and ocular surface organoids that recapitulate epidermal stratification, conjunctival differentiation, and tissue fusion defects.
• Ocular microphysiological systems (organ‑on‑chip) modeling dermal‑ocular adhesion, tear film dynamics, and corneal‑eyelid interactions.
• Ex vivo ocular tissue explant systems for testing tissue remodeling and fusion‑promoting agents.

Each model is fully characterized via histopathology, immunofluorescence, qPCR, and electron microscopy to ensure fidelity to human cryptophthalmos phenotypes.

In Vitro Efficacy Screening and Pharmacology Services

Protheragen offers quantitative in vitro efficacy testing across all therapeutic modalities for cryptophthalmos:

• Small‑molecule screening for compounds that restore tissue fusion, reduce fibrosis, or promote eyelid morphogenesis.
• Gene therapy testing for viral vector‑mediated gene replacement, base editing, or prime editing in mutant organoids.
• Biologic and antisense oligonucleotide (ASO) evaluation for splicing modulation, protein expression correction, or developmental signaling regulation.
• Regenerative medicine screening for growth factors, peptides, or small molecules that induce conjunctival sac formation or corneal epithelial repair.

We provide concentration‑response analysis, kinetic profiling, and combination therapy assessment, with readouts including morphological rescue, gene expression normalization, protein function restoration, and tissue architecture repair.

Ocular Pharmacokinetics and Formulation Optimization Services

We support the design and optimization of ophthalmic formulations tailored to the cryptophthalmos ocular surface. Services include:

• In vitro drug release and permeability testing across abnormal ocular epithelia.
• Ocular tissue distribution modeling for anterior segment and ocular surface delivery.
• Formulation development for topical solutions, suspensions, in situ gels, and mucoadhesive systems.
• Stability testing under accelerated and long‑term storage conditions.

These studies ensure optimal bioavailability to dysplastic tissues, supporting consistent efficacy in preclinical models.

Safety Pharmacology and In Vitro Toxicology Services

Protheragen conducts specialized ocular safety assessment to identify off‑target effects in cryptophthalmos‑relevant tissues:

• In vitro cytotoxicity and irritancy testing in human ocular surface and eyelid cells.
• Genotoxicity and mutagenicity screening for gene‑therapy and small‑molecule candidates.
• Histopathological safety evaluation in 3D organoids to assess tissue damage or inflammation.
• Functional safety testing for effects on cell migration, proliferation, and differentiation.

All studies follow standardized protocols to generate safety margins and de‑risk therapeutic candidates.

Translational Biomarker Development and Quantitative Analysis Services

We identify and validate predictive pharmacodynamic biomarkers for cryptophthalmos:

• Gene expression biomarkers for developmental pathway activity.
• Protein biomarkers for extracellular matrix remodeling and tissue fusion.
• Histomorphometric biomarkers for eyelid structure, conjunctival sac formation, and corneal clarity.
• Imaging biomarkers for in vitro model phenotypic assessment.

These biomarkers enable objective, quantitative evaluation of therapeutic response in preclinical studies.

Diagnostics Development

• Karyotype Analysis Service
• Omics Analysis Service
• Biomarker Development Service
• Artificial Intelligence Service
• Customized Diagnostics Development

Therapeutic Development

• Small Molecule Drug
• Cell Therapy
• Gene Therapy
• Therapeutic Antibody
• Therapeutic Peptide
• Therapeutic Protein
• Customized Therapy Development

Disease Models

• Frem2^R725X/R2156W Mouse Models: Generated using gene editing technology.
• Fras1^–/– Mouse Models: Generated by homologous recombination in mouse embryonic stem cells.

We conduct a range of in vitro and in vivo studies to assess the effectiveness of potential therapeutics. This includes cell-based assays to evaluate the impact of drugs on ocular cell lines and animal models to study the therapeutic effects in a living system. If you are interested in our services, please feel free to contact us.

References

• Yu, Qian, et al. "A homozygous mutation p. Arg2167Trp in FREM2 causes isolated cryptophthalmos." Human molecular genetics 27.13 (2018): 2357-2366.
• Liu, Zhaochuan, et al. "Reconstruction strategy in isolated complete Cryptophthalmos: a case series." BMC ophthalmology 19 (2019): 1-7.
• Landau-Prat, Daphna, et al. "Cryptophthalmos: associated syndromes and genetic disorders." Ophthalmic Genetics 44.6 (2023): 547-552.